Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC011 in relapsed or refractory follicular lymphoma
NCT07360288Phase 2Not yet recruiting
- Sponsor
- TiCARos Therapeutics
- Start
- Mar 2026
- Primary completion
- May 2028
01
Overview
Phase 2, open-label, single-arm trial in follicular lymphoma (FL), sponsored by TiCARos Therapeutics. Primary endpoint: Objective Response Rate at 96 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07360288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07360288.